Search all trials

Find therapies in clinical trials near you

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Gastroenteropancreatic neuroendocrine tumour disease

Recruiting

Registered drugNo placebo

Study of Lutetium-177-DOTA-TATE with octreotide LAR in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) with high disease burden

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Dimeticone

Contact Research Centre

Gastroenteropancreatic neuroendocrine tumour disease+1

Recruiting

Registered drugNo placebo

Study of Gallium (68Ga) edotreotide, Fluorocholine (18F) and Fludeoxyglucose (18F) PET imaging for detection and staging of liver cancer and gastro-entero-pancreatic tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Fludeoxyglucose (18F)

Contact Research Centre

Gastroenteropancreatic neuroendocrine tumour disease+1

Recruiting

Registered drugNo placebo

Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab

Contact Research Centre

Gastroenteropancreatic neuroendocrine tumour disease+6

Recruiting

Registered drugNo placebo

Study of 64Cu-DOTATATE and 18F-FDG PET/CT imaging to predict disease progression in patients with neuroendocrine neoplasms

Registered drugNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:Dotatate

Contact Research Centre

Gastroenteropancreatic neuroendocrine tumour disease+6

Recruiting

Registered drugNo placebo

Study of Combined Imaging with Hyperpolarized [1-13C]Pyruvate and Fludeoxyglucose (18F) for Cancer Detection in Patients with Breast Cancer, Neuroendocrine Tumors, Lymphomas, or Sarcomas

Registered drugNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:Pyruvic Acid

Contact Research Centre

Gastroenteropancreatic neuroendocrine tumour disease

Recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of Cabozantinib and Lanreotide for Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Cabozantinib

Contact Research Centre

Gastroenteropancreatic neuroendocrine tumour disease

Recruiting

Registered drugNo placebo

Study of Intra-Arterial Infusion of Lutetium (177Lu) Oxodotreotide for Adults with Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Amlodipine Besilate

Contact Research Centre

Gastroenteropancreatic neuroendocrine tumour disease+2

Recruiting

Registered drugNo placebo

Study on Continuing Somatostatin Analogues with Sunitinib, Octreotide, and Lutetium (177Lu) Oxodotreotide for Patients with Neuroendocrine Tumors

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Everolimus

Contact Research Centre

Gastroenteropancreatic neuroendocrine tumour disease

Not yet recruiting

Registered drugNo placebo

68Ga-DOTATATE PET/CT Prognostic Assessment in Patients with Well-Differentiated Grade 2 Gastroenteropancreatic Neuroendocrine Tumors Treated with 177Lu-oxodotreotide and Edotreotide

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Edotreotide

Contact Research Centre

Gastroenteropancreatic neuroendocrine tumour disease+5

Not yet recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of Domvanalimab and Zimberelimab for Adults with Advanced Rare Cancers Resistant to Standard Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Domvanalimab

Contact Research Centre

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Registered drugNo placebo

Study on RYZ101 for Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors After Previous Treatment

Registered drugNo placebo

Belgium

Participants:18–64 years
Substances:Everolimus

Contact Research Centre

Gastroenteropancreatic neuroendocrine tumour disease+1

Not recruiting

Registered drugNo placebo

Study on the Effectiveness of Lutetium (177Lu) Oxodotreotide and Octreotide in Patients with Advanced GEP-NET Tumors (Grade 2 and 3)

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Octreotide

Contact Research Centre

Find therapies in clinical trials near you

16 trials match your criteria

Gastroenteropancreatic neuroendocrine tumour disease

Study of Lutetium-177-DOTA-TATE with octreotide LAR in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) with high disease burden

Gastroenteropancreatic neuroendocrine tumour disease+1

Study of Gallium (68Ga) edotreotide, Fluorocholine (18F) and Fludeoxyglucose (18F) PET imaging for detection and staging of liver cancer and gastro-entero-pancreatic tumors

Gastroenteropancreatic neuroendocrine tumour disease+1

Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas

Gastroenteropancreatic neuroendocrine tumour disease+6

Study of 64Cu-DOTATATE and 18F-FDG PET/CT imaging to predict disease progression in patients with neuroendocrine neoplasms

Gastroenteropancreatic neuroendocrine tumour disease+6

Study of Combined Imaging with Hyperpolarized [1-13C]Pyruvate and Fludeoxyglucose (18F) for Cancer Detection in Patients with Breast Cancer, Neuroendocrine Tumors, Lymphomas, or Sarcomas

Gastroenteropancreatic neuroendocrine tumour disease

Study on the Safety and Effectiveness of Cabozantinib and Lanreotide for Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors

Gastroenteropancreatic neuroendocrine tumour disease

Study of Intra-Arterial Infusion of Lutetium (177Lu) Oxodotreotide for Adults with Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases

Gastroenteropancreatic neuroendocrine tumour disease+2

Study on Continuing Somatostatin Analogues with Sunitinib, Octreotide, and Lutetium (177Lu) Oxodotreotide for Patients with Neuroendocrine Tumors

Gastroenteropancreatic neuroendocrine tumour disease

68Ga-DOTATATE PET/CT Prognostic Assessment in Patients with Well-Differentiated Grade 2 Gastroenteropancreatic Neuroendocrine Tumors Treated with 177Lu-oxodotreotide and Edotreotide

Gastroenteropancreatic neuroendocrine tumour disease+5

Study on the Safety and Effectiveness of Domvanalimab and Zimberelimab for Adults with Advanced Rare Cancers Resistant to Standard Treatment

Gastroenteropancreatic neuroendocrine tumour disease

Study on RYZ101 for Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors After Previous Treatment

Gastroenteropancreatic neuroendocrine tumour disease+1

Study on the Effectiveness of Lutetium (177Lu) Oxodotreotide and Octreotide in Patients with Advanced GEP-NET Tumors (Grade 2 and 3)

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.